Unternehmensübersicht
Equillium, Inc. operates as a clinical-stage biotechnology company focused on developing therapeutics for severe autoimmune and inflammatory disorders, specifically targeting unmet medical needs within the United States healthcare landscape. The company functions within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself to address conditions where existing treatment options are limited or non-existent. Its current market capitalization stands at $113.81M, while specific metrics regarding annual revenue and employee count are not publicly disclosed in the available financial data. These valuation figures indicate that the company is in an early-to-mid stage of development typical for clinical-stage entities, where value is derived primarily from pipeline potential rather than established commercial revenue streams or large-scale operational infrastructure.
Finanzielle Gesundheit
The reported net income for the trailing twelve months is a loss of $22,398,000, while EBITDA reflects a loss of $23,518,000, highlighting a significant gap between top-line activity and bottom-line profitability that points to substantial cost structures associated with drug development and clinical trials. Free cash flow for the same period stands at $-14,327,250, indicating that the company is burning cash to fund its operations and research activities, which limits immediate financial flexibility but is often necessary for growth-stage biotech firms. The company reports zero margins across the board, with Gross Margin, Operating Margin, and Profit Margin all recorded at 0.0%, a standard characteristic for biotechnology companies prior to commercial product launch where revenue is negligible relative to operational expenses. Regarding liquidity, Equillium holds $30.28M in cash against total debt of $719,000, resulting in a debt-to-equity ratio of 2.51, which suggests a highly leveraged capital structure relative to equity, though the absolute debt level is manageable given the cash reserves. The current ratio is an exceptionally high 10.58, signaling robust short-term liquidity where current assets vastly exceed current liabilities, providing a wide buffer against immediate obligations. Return on Equity is -94.0% and Return on Assets is -51.4%, metrics that reveal that management has yet to generate positive returns on shareholder capital or asset base, a common occurrence in pre-commercialization phases before the lead product candidate generates sales.
Bewertungsanalyse
The Trailing P/E ratio is not applicable (N/A) due to the absence of positive earnings, whereas the Forward P/E is listed at -8.71, a negative figure that implies the market expects future earnings to remain negative or is pricing in significant time to profitability. The Price to Book ratio stands at 3.87, indicating that the market values the company at nearly four times its book value, reflecting a premium placed on the intellectual property and clinical pipeline assets rather than current tangible net worth. Alternative valuation metrics such as Price to Sales and EV/EBITDA are also not applicable or negative, specifically showing an EV/EBITDA of -3.58, which suggests that traditional earnings-based valuation models are not suitable for assessing the company at this stage of its lifecycle. The stock has exhibited significant volatility over the past year, trading between a 52-week low of $0.27 and a 52-week high of $2.70, meaning the current valuation sits somewhere within this wide range depending on the specific trading day. The Beta of 1.74 indicates that the stock's price volatility is 74% higher than the broader market, exposing investors to substantial price swings that correlate less with general market movements and more with specific biotech sector dynamics or company-specific clinical developments.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, which is consistent with the company's status as a clinical-stage entity that has not yet generated meaningful commercial revenue to measure growth rates against. Since the company has not yet generated positive earnings, there is no dividend yield or payout ratio, with the payout ratio explicitly stated as 0.0%, meaning the company reinvests all available capital, including its cash reserves, back into research and development rather than distributing income to shareholders. The lack of dividend payments is a strategic necessity for a clinical-stage biotechnology firm that must retain capital to advance its lead product candidate, Itolizumab, through clinical trials and regulatory approval processes. The overall growth and income profile is characterized by a total reliance on capital raising and internal cash reserves to fuel expansion, as traditional income generation mechanisms like dividends are unavailable and historical growth metrics cannot yet be quantified.